THE EFFICIENCY OF STANDARD THERAPY AND ALPHA-LIPOIC ACID IN PATIENTS WITH STABLE ISCHEMIC HEART DISEASE WITH CONCOMITANT DIABETES MELLITUS TYPE 2
DOI:
https://doi.org/10.11603/1811-2471.2017.v1.i3.7954Keywords:
stable ischemic heart disease, left ventricle diastolic dysfunction, diabetes mellitus type 2, diabetic neuropathy of the lower extremities, oxygenation of arterial and venous blood, alpha-lipoic acid.Abstract
The use of α-lipoic acid in patients with stable ischemic heart disease (IHD) with diabetic neurophaty of lower extremities considerably promotes the oxygen providing of peripheral tissues.
The aim of the work was to promote efficiency of treatment of neurophaty for patients with stable IHD and concomitant type 2 diabetes mellitus.
Materials and methods. 54 patients with stable IHD and concomitant type 2 diabetes mellitus, complicated neurophaty were inspected. Echocardioscopy, estimation of neurological symptoms, research of esthesiaes, and also estimation of parameters of oxigenation of arterial and venous blood were conducted. All patients got standard therapy of stable IHD and α-lipoic acid in day's dose 600 mgs during 1 month.
Results. Complex application of α-lipoic acid with standard therapy of stable IHD considerably improves the neurological symptomatology of neurophaty and oxygen providing of lower extremities.
References
Mankovskyi, B.M., (2013). Likuvannia diabetychnoi polineiropatii: yaka dokazova baza? [Treatment of diabetic polyneuropathy: what is the evidence base?]. Liky Ukrainy – Medicine of Ukraine, 10 (156), 30-32 [in Ukrainian].
Pankiv, V.I., & Khutorska, L.A. (2013). Ryzyk zahalnoi i sertsevo-sudynnoi smertnosti, osnovnykh sertsevo-sudyn- nykh podii u khvorykh na tsukrovyi diabet 2 typu zalezhno vid vyboru terapii pislia vstanovlennia diahnozu [Risk overall and cardiovascular mortality, major cardiovascular events in patients with type 2 diabetes, depending on the choice of therapy after diagnosis]. Bukovynskyi medychnyi visnyk – Bu- kovyna Medical Journal, 1, 80-83 [in Ukrainian].
Pankiv, V.I., (2014). Upravlinnia diabetychnoiu neiropatiieiu: oriientatsiia na patsiienta [Management of diabetic neuropathy: patient’s orientation]. Mizhnarodnyi endokrynolohichnyi zhurnal – International Endocrinology Journal, 3 (51), 47-48 [in Ukrainian].
Unifikovanyi klinichnyi protokol pervynnoi, vtorynnoi (spetsializovanoi) ta tretynnoi (vysokospetsializovanoi) me- dychnoi dopomohy. Stabilna ishemichna khvoroba sertsia [Unified clinical protocol of primary, secondary (specialized) and tertiary (highly specialized) medical aid. Stable ischemic heart disease]. Kyiv [in Ukrainian].
Fomina, I.G., Saltikov, B.B., Koroleva, T.V. (2014). Di- agnostika mikrotsyrkulyatornykh narusheniy u bolnykh s sakharnym diabetom 2 tipa i ishemicheskoy boleznyu serd- tsa [Diagnosis of microcirculatory disorders in patients with type 2 diabetes mellitus and coronary heart disease]. Klini cheskaya meditsyna – Clinical Medicine, 82 (2), 36-39 [in Russian].
Wu, S., & Ren, J., (2014). Benfotiamine alleviates diabetes-induces cerebral oxidative damage independent of advanced glycation end-product, tissue factor. Neurosc. Lett., 394, 158-162.
(2007). Guidelines on diabetes, pre-diabetes and cardiovascular disease: executive summary. The Task Force on Diabetes and Cardiovascular Diseas of the European Society of Cardilogy (ESC) and of the European Associa- tion for the Study of Diabetes (EASD). European Heart Journal, 28, 88-136
